{
    "name": "darbepoetin alfa",
    "comment": "Rx",
    "other_names": [
        "Aranesp"
    ],
    "classes": [
        "Hematopoietic Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/aranesp-darbepoetin-alfa-342150",
    "pregnancy": {
        "common": [
            "Limited available data on pregnant women are insufficient to determine a drug-associated risk of major birth defects or miscarriage; in animal reproductive and developmental toxicity studies, drug increased early post-implantation loss at doses approximating clinical recommended starting doses; consider benefits and risks for the mother and possible risks to fetus when prescribing to a pregnant woman"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "When Aranesp was administered intravenously during organogenesis to pregnant rats (gestational days 6 to 15) and rabbits (gestational days 6 to 18), there was no evidence of embryofetal toxicity or other adverse outcomes at intravenous doses tested, up to 20 mcg/kg/day; no significant placental transfer was observed in rats; placental transfer was not evaluated in rabbits",
                    "In a peri/postnatal development study, pregnant female rats received therapy intravenously every other day from implantation (day 6) throughout pregnancy and lactation (day 23); the lowest dose tested, 0.5 mcg/kg, did not cause fetal toxicity; this dose is approximately equivalent to clinical recommended starting dose; at maternal doses of 2.5 mcg/kg and higher, pups had decreased fetal body weights, which correlated with a slight increase in the incidence of fetal deaths, as well as delayed eye opening and delayed preputial separation; the offspring (F1 generation) of treated rats were observed postnatally; rats from F1 generation reached maturity and were mated; no treatment related effects were apparent for their offspring (F2 generation fetuses)"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of drug in human milk, effects on breastfed child, or on milk production; the developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Chronic kidney disease (CKD) ",
                    "description": [
                        "In controlled trials with CKD patients, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to a target hemoglobin level of greater than 11 g/dL",
                        "No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks",
                        "Use the lowest dose sufficient to reduce the need for red blood cell (RBC) transfusions"
                    ]
                },
                {
                    "type": "Cancer ",
                    "description": [
                        "ESAs shortened overall survival and/or increased the risk of tumor progression in some clinical studies in patients with breast, head, and neck; lymphoid; non-small cell lung; and cervical cancers",
                        "Prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense ESAs to patients with cancer",
                        "Use the lowest dose to avoid RBC transfusions",
                        "Use ESAs only for anemia from myelosuppressive chemotherapy",
                        "ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure",
                        "Discontinue following the completion of a chemotherapy course"
                    ]
                },
                {
                    "type": "Cardiovascular Events",
                    "description": [
                        "Increased risk of serious cardivascular events including stroke and thromboembolic events"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Uncontrolled hypertension",
                "Hypersensitivity to any component",
                "Pure red cell aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased mortality, myocardial infarction, stroke, and thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit (see Black Box Warnings)",
                "Hypertensive encephalopathy and seizures reported in patients with CKD; appropriately control hypertension prior to initiation of and during treatment; reduce or withhold Aranesp if blood pressure becomes difficult to control; advise patients of importance of compliance with antihypertensive therapy and dietary restrictions",
                "For lack or loss of hemoglobin response to therapy, initiate a search for causative factors (eg, iron deficiency, infection, inflammation, bleeding); if typical causes of lack or loss of hemoglobin response are excluded, evaluate for PRCA; in absence of PRCA, follow dosing recommendations for management of patients with insufficient hemoglobin response to therapy",
                "Use caution in known porphyria, sickle cell anemia, thalassemia",
                "Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur; immediately and permanently discontinue therapy and administer appropriate therapy if a serious allergic or anaphylactic reaction occurs",
                "Decrease dose if Hgb increase exceeds 1 g/dL in any 2 wk period",
                "Increased mortality and/or increased risk of tumor progression or recurrence in patients with cancer",
                "Increases the risk for seizures in patients with CKD; increase monitoring of these patients for changes in seizure frequency or premonitory symptoms",
                "If severe anemia and low reticulocyte count develop during treatment, withhold therapy and evaluate for pure red cell aplasia",
                "Blistering and skin exfoliation reactions including erythema multiforme and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN), reported in the post-marketing setting; discontinue therapy immediately if a severe cutaneous reaction, such as SJS/TEN, suspected",
                "Two different excipients available: polysorbate 80 or human albumin",
                "May use supplemental iron if serum ferritin <100 mcg/L [0.225 pmol/L] or serum transferrin saturation <20%",
                "IV route preferred for patients on hemodialysis",
                "Patients may require adjustments in their dialysis prescriptions after initiation of therapy; patients receiving treatment may require increased anticoagulation with heparin to prevent clotting of extracorporeal circuit during hemodialysis",
                "Autoinjector for SC administration only",
                "Dose increase no more frequently than once monthly"
            ],
            "specific": [
                {
                    "type": "Pure red cell aplasia",
                    "description": [
                        "Cases of PRCA and severe anemia, with or without other cytopenias that arise following development of neutralizing antibodies to erythropoietin reported predominantly in patients with CKD receiving ESAs by subcutaneous administration; also reported in patients receiving therapy for anemia related to hepatitis C treatment (indication not approved)",
                        "If severe anemia and low reticulocyte count develop during treatment, withhold therapy and evaluate patients for neutralizing antibodies to erythropoietin; contact Amgen (1-800-77-AMGEN) to perform assays for binding and neutralizing antibodies",
                        "Permanently discontinue therapy in patients who develop PRCA following treatment; do not switch patients to other ESAs"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "33"
        },
        {
            "name": "Diarrhea",
            "percent": "22"
        },
        {
            "name": "Edema",
            "percent": "21"
        },
        {
            "name": "Fever",
            "percent": "19"
        },
        {
            "name": "Dizziness",
            "percent": "14"
        },
        {
            "name": "Arthralgia",
            "percent": "13"
        },
        {
            "name": "Headache",
            "percent": "12"
        },
        {
            "name": "Death",
            "percent": "10"
        },
        {
            "name": "Infectious disease",
            "percent": "24"
        },
        {
            "name": "Hyper",
            "percent": "20"
        },
        {
            "name": "Hypotension",
            "percent": "17"
        },
        {
            "name": "Spasm",
            "percent": "15"
        },
        {
            "name": "Upper respiratory infection",
            "percent": "14"
        },
        {
            "name": "Headache",
            "percent": "11"
        },
        {
            "name": "Diarrhea",
            "percent": "10"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Peripheral edema",
            "percent": "3.7"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "2"
        },
        {
            "name": "Myalgia",
            "percent": "2"
        },
        {
            "name": "Hypertension",
            "percent": "1.3"
        },
        {
            "name": "Pneumonia",
            "percent": "9"
        },
        {
            "name": "Dyspnea",
            "percent": "8"
        },
        {
            "name": "Vomiting",
            "percent": "7"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "6"
        },
        {
            "name": "Arthralgia",
            "percent": "6"
        },
        {
            "name": "Cough",
            "percent": "5.6"
        },
        {
            "name": "Fatigue",
            "percent": "5"
        },
        {
            "name": "Limb pain",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "0.6"
        },
        {
            "name": "Fever",
            "percent": "0.6"
        },
        {
            "name": "Death",
            "percent": "1"
        },
        {
            "name": "Edema",
            "percent": "1"
        },
        {
            "name": "Anemia",
            "percent": "1"
        },
        {
            "name": "DVT",
            "percent": null
        },
        {
            "name": "red cell aplasia",
            "percent": null
        },
        {
            "name": "Cardiac arrest",
            "percent": null
        },
        {
            "name": "Cardiac dysrhythmia",
            "percent": null
        },
        {
            "name": "Congestive heart failure",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "CVA",
            "percent": null
        },
        {
            "name": "Hypertensive encephalopathy",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Hypertensive encephalopathy",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Transient ischemic attack",
            "percent": null
        }
    ]
}